Qizheng Tibetan Medicine: Digging Deeply into the Value of the Whole Industry Chain of Ethnic Medicine

The business club reported on July 25th that it has an ancient Tibetan medicine with a history of more than 2,300 years and is entering a stage of rapid development with the goal of industrial modernization, scale, intensification, and internationalization. As the largest Tibetan medicine company in Tibet, Qizheng Tibetan Medicine has accelerated the establishment of competitive advantages in resources and relied on the capital market platform to dig deeper into the value of the entire industry chain of the national pharmaceutical industry.

Qizheng Tibetan Medicine has long focused on the pain drug market. Its main products include Qizhengxiaotong plaster, Qingpeng ointment and other external and oral Tibetan medicines, and Tibetan medicines, among which the external painkillers represented by Qizhenxiaotong plaster are The topical painkiller market in China ranks first in terms of sales for many years. In the operating revenue of 523 million yuan of Qizheng Tibetan Medicine in 2010, the total operating income of paste products and ointment products accounted for 85.7%.

Under the vigorous promotion of Tibet's Tibetan medicine industry in the Tibet Autonomous Region, at the end of last year, other Tibetan medicine companies in the Qizheng Tibetan Medicine Union Area jointly initiated the establishment of the Tibetan Utopia Pharmaceutical Industry Group together with the Autonomous Region Investment Company and state-funded companies. Pharmaceutical Holdings 80%. According to the company, the new group will rely on the unique medical resources of the Tibetan Plateau to further tap into the overall market value of the industrial chain, laterally tap the market value of Tibetan medicine and Tibetan medicine in the field of treatment and health care, and expand the medicine of Tibetan medicine in medicine. Market space in the field.

In June last year, Qizheng Tibetan Medicine invested 180 million yuan to build a world-class pollution-free Chinese medicine decoction pieces and deep-processing production base in Gansu. After completion, it is estimated that the annual operating income will reach 460 million yuan. In March of this year, Qi Xiqi, a wholly-owned subsidiary of Qizheng Medicines, is investing 27.5 million yuan in holding 55% and two other shareholders forming Ningxia Qizheng Shahu Industrial Co., Ltd., creating China's most advantageous country of origin. Brand supplier.

In addition to the existing plasters and ointment products, the development of the entire industry chain of Sino-Tibetan medicinal materials covering cultivation, R&D, production and marketing integration is expected to become one of the important sources of profit for Qizheng Tibetan Medicine in the future.